www.ijarp.com ISSN 2456-9992 Page: 01-09

International Journal Advanced Research Publications

Review Article

Volume: 02
Issue: 07

ROLE OF EPIGENETIC MODULATORS IN CANCER THERAPY CURRENT STATUS AND FUTURE DIRECTIONS

A. Subashree*[1], Dr. V. Kalvimoorthi[2], Mr. L. Gopi[3]

[1]M.Pharm First Year Department of Pharmacology, [2] Professor Cum Hod Department of Pharmaceutics, [3]Assistant Professor Department of Pharmaceutics.

Aadhibhagawan College of Pharmacy, Rantham, Thiruvannamalai.

Article Received: 18 June 2026, Article Revised: 08 July 2026, Published on: 28 July 2026

***Corresponding Author: A. Subashree**

M. Pharm First Year Department of Pharmacology, Aadhibhagawan College of Pharmacy, Rantham, Thiruvannamalai.

Doi: https://doi-doi.org/101555/ijarp.6889

ABSTRACT

Cancer arises through a combination of genetic mutations and epigenetic dysregulation that influences gene expression, chromatin organization, and cellular identity Unlike genetic alterations, epigenetic changes are reversible, offering therapeutic opportunities to reprogram aberrant transcriptional states. Epigenetic modulators-agents that target DNA methylation, histone modification enzymes, chromatin readers, and non-coding RNA networks-have emerged as a novel class of anti-cancer therapeutics. Although several epigenetic drugs are clinically approved, their broader application is constrained by specificity, resistance, and biomarker challenges. This article reviews the mechanisms of epigenetic dysregulation in cancer, summarizes Current clinical experience with epigenetic modulators, highlights combination strategies, discusses key limitations, and outlines future directions for research and clinical translation.

KEYWORDS: Cancer, Epigenetic, DNA.

1. INTRODUCTION

Cancer is fundamentally a disease of dysregulated gene expression. In addition to irreversible genetic mutations, reversible epigenetic alterations play pivotal roles in tumor initiation, progression, and therapy resistance. Epigenetics encompasses heritable but reversible changes in chromatin structure and function, including DNA methylation, histone post-translational modifications (PTMs), chromatin remodeling, and regulation by non-coding

RNAs such as microRNAs (miRNAs) and long non-coding RNAs (IncRNAs). Because these processes are dynamic and modifiable, they present attractive targets for therapeutic intervention. Epigenetic modulators have therefore entered clinical oncology as single agents or in combination regimens aimed at restoring normal transcriptional programs and sensitizing tumors to cytotoxic and inununе-based therapies.

1.1 Normal Cell and Cancer Cell Development



Fig: 1 Normal Cell Development Abnormal Cell Growth.

1.2 Epigenetic Dysregulation in Cancer

Normal cellular identity and gene expression depend on tightly controlled epigenomic landscapes. Cancer cells, however, exhibit pervasive epigenetic defects that contribute to hallmark features of malignancy. Global DNA hypo methylation, which destabilizes the genome and activates oncogenic repeats.

Promoter hyper methylation of tumor Suppressor genes, leading to gene silencing. Aberrant histone modification patterns, including loss of activating marks (e.g., H3KAme3) and gain of repressive marks (e.g., H3K27me3). Disrupted chromatin remodeling complexes that impair normal nucleosome dynamics. Dysregulated non-coding RNA networks that control key pathways in cell cycle, apoptosis, and metastasis.

These changes facilitate uncontrolled proliferation, evasion of apoptosis, angiogenesis, metastasis, and therapeutic resistance. Epigenetic drugs aim to reverse aberrant chromatin states by targeting enzymes and readers involved in epigenomic regulation.

1.3 DNA Methyltransferase Inhibit013 (DNMTis)

DNA methyltransferases (DNMTS) add methyl groups to cytosines in CpG dinucleotides, often leading to gene silencing when present in gene promoters. DNMT inhibitors, such as azacitidine and decitabine, incorporate into DNA and trap DNMTS, resulting in passive demethylation during cell division. This reactivates silenced tumor suppressor genes, promotes differentiation, and induces apoptosis, particularly in hematologic malignancies.

1.4 Histone Deacetylase Inhibitors (HDACis)

Histone acetylation relaxes chromatin and facilitates transcription, while histone deacetylases (HDACs) remove acetyl groups, Condensing chromatin and repressing gene expression. HDAC inhibitors (e.g., vorinostat, romidepsin, belinostat, panobinostat) increase histone acetylation, resulting in transcriptional activation of tumor suppressors, cell cycle arrest, apoptosis, and immune modulation.

Histone Methyltransferase and Demethylase Modulators. Histone methylation can be activating or repressive based on the residue and mark. Enzymes like EZH2, the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), deposit repressive H3K27me3 marks. Small-molecule EZH2 inhibitors and demethylase (e.g. , LSD I/KDMIA) inhibitors aim to reverse aberrant methylation, restoring healthy gene expression.

Chromatin Reader Inhibitors and Emerging Targets Proteins that "read" histone marks, such as bromodomain and extraterminal (BET) proteins, recruit transcriptional machinery to acetylated chromatin. BET inhibitors disrupt oncogenic transcriptional programs. Additional emergent targets include chromatin remodelers (e.g., SWi/SNF components) and non-coding RNA therapies, including synthetic miRNA mimics or antisense oligonucleotides that restore regulatory balance.

1.5 Current Clinical Applications

Table: 1 Approved Epigenetic Drugs.

DRUG CLASS	CURRENT	INDICATIONS
DNMT ilmibitors	Azacitidine	Myelodysplastic syndromes (MDS), AML in older adults
	Decitabine	MDS, AML
HDAC	Vorinostat	Cutaneous T-cell I homa
	Romidepsin	Peripheral and cutaneous T-cell
	Belinostat	Peripheral T-cell

		I homa
	Panobinostat	Multiple myeloma (in combination

These agents have demonstrated efficacy predominantly in hematologic malignancies, where epigenetic dysregulation is particularly pronounced.

2. COMBINATION STRATEGIES

- Epigenetic modulators enhance the activity of standard therapies: Chemotherapy - DNMTis and HDACis may increase chemosensitivity.
- Targeted therapy— Epigenetic drugs can prime chromatin for targeted agents.
- Immunotherapy - Epigenetic agents upregulate antigen presentation and modulate the tumor microenvironment, enhancing immune checkpoint blockade efficacy.
- These synergistic effects support combinatorial regimens that may Overcome intrinsic resistance mechanisms.

3. MECHANISMS OF THERAPEUTIC ACTION:

Epigenetic drugs exert anti-tumor effects through multiple pathways:

- Reactivation of tumor suppressor genes silenced by aberrant methylation or histone marks.
- Induction of cell cycle arrest and apoptosis via transcriptional reprogramming.
- Chromatin remodeling that facilitates DNA damage response and repair.
- Immunomodulation, including upregulation of MHC-I/ll and neoantigen expression.
- Differentiation induction, particularly in malignancies like acute myeloid leukemia where differerntiation is blocked.
- By targeting the epigenomic landscape, these agents alter fundamental cancer cell biology beyond single signaling pathways.

4. CHALLENGES AND LIMITATIONS:

Despite promising activity, epigenetic therapies face several obstacles:

Specificity and Off-Target Effects Epigenetic enzymes are also essential in normal tissue homeostasis. Broad inhibition may lead to toxicities such as cytopenias, cardiac events (with some HDACis), and gastrointestinal symptoms.

Lack of Predictive Biomarkers

Robust biomarkers to predict response are limited. Efforts to define methylation signatures, chromatin accessibility profiles, and transcriptional states are ongoing to better stratifr patients.

Resistance Mechanisms Cancer cells may develop resistance through compensatory epigenetic pathways mutations in epigenetic targets adaptive chromatin plasticity Understanding these mechanisms will enable rational combination approaches and next-generation inhibitors.

5. FUTURE DIRECTIONS

Precision Epigenomics: Emerging technologies such as single-cell epigenomics, methylome profiling, and ATAC-seq will help tailor epigenetic interventions to tumor subtypes and dynamic states.

Next-Generation Modulators: Development of selective modulators targeting specific histone marks or dual inhibitors (e.g., DNMT + HDAC) may improve efficacy with reduced toxicity. PROTACs targeting epigenetic regulators represent an innovative modality to degrade disease-promoting proteins.

Epigenetic-Based Immunomodulation: Optimizing epigenetic priming to enhance antigenicity and immune recognition may Overcome resistance to immunotherapies.

Non-Coding RNA Therapeutics: Advances in delivery platforms (e.g., lipid nanoparticles) could enable effective modulation of miRNA/IncRNA networks that govern oncogenic and tumor suppressive circuits.

Rational Combination Regimens: Integrating epigenetic drugs with DNA damage agents, immune stimulators, and targeted therapies in personalized combination regimens promises to maximize therapeutic benefit while minimizing resistance.

6. DISCUSSION

The growing understanding of cancer biology has established that tumor development is driven not only by irreversible genetic mutations but also by reversible epigenetic alterations that regulate gene expression without changing the DNA sequence. Unlike conventional genetic therapies, epigenetic interventions offer the unique advantage of reversing abnormal transcriptional programs, making epigenetic modulators attractive therapeutic candidates.

Over the past decade, advances in molecular oncology have demonstrated that DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs collectively influence tumor initiation, progression, metastasis, and therapeutic resistance.

Among currently available epigenetic therapies, DNA methyltransferase inhibitors (DNMT inhibitors) such as azacitidine and decitabine have shown significant clinical benefits in patients with myelodysplastic syndromes and acute myeloid leukemia. These agents restore the expression of silenced tumor suppressor genes through DNA demethylation, thereby promoting apoptosis and cellular differentiation. Similarly, histone deacetylase inhibitors, including vorinostat, romidepsin, belinostat, and panobinostat, have demonstrated efficacy in T-cell lymphomas and multiple myeloma by altering chromatin accessibility and reactivating genes involved in cell-cycle regulation and apoptosis. Nevertheless, their therapeutic success has been considerably greater in hematological malignancies than in solid tumors, suggesting that tumor-specific epigenetic landscapes influence treatment responsiveness.

Emerging epigenetic targets such as enhancer of zeste homolog 2 (EZH2), lysine-specific demethylase 1 (LSD1), bromodomain and extraterminal (BET) proteins, and chromatin remodeling complexes have expanded the scope of epigenetic therapy. Selective inhibitors against these regulators have demonstrated encouraging preclinical and early clinical outcomes by suppressing oncogenic transcriptional networks while preserving normal cellular functions. In addition, therapeutic strategies targeting microRNAs and long non-coding RNAs are gaining attention because these molecules regulate multiple oncogenic signaling pathways simultaneously. Although many of these approaches remain under clinical investigation, they represent promising avenues for precision oncology.

One of the most important developments in recent years has been the integration of epigenetic modulators with conventional cancer treatments. Numerous studies have demonstrated that epigenetic drugs sensitize cancer cells to chemotherapy, radiotherapy, targeted therapy, and immune checkpoint inhibitors by increasing antigen presentation, restoring immune surveillance, and modifying the tumor microenvironment. Epigenetic priming has also been shown to overcome acquired drug resistance by reprogramming resistant cancer cells into therapy-sensitive phenotypes. These observations have encouraged the design of combination regimens that aim to achieve greater clinical efficacy than monotherapy.

Despite these advances, several challenges continue to limit the widespread clinical application of epigenetic therapies. The lack of tumor specificity often results in off-target effects because epigenetic enzymes regulate normal physiological processes in healthy tissues. Adverse effects including hematological toxicity, gastrointestinal disturbances, fatigue, and cardiotoxicity remain important concerns during long-term treatment. Furthermore, resistance mechanisms involving compensatory epigenetic pathways, mutations in target enzymes, and chromatin plasticity frequently reduce treatment effectiveness. The absence of validated predictive biomarkers also limits patient selection and therapeutic optimization.

Recent technological developments are expected to address many of these limitations. Single-cell epigenomic sequencing, methylome analysis, chromatin accessibility profiling (ATAC-seq), and multi-omics integration provide detailed insights into tumor heterogeneity and may facilitate personalized epigenetic therapy. Novel drug discovery approaches, including proteolysis-targeting chimeras (PROTACs), dual epigenetic inhibitors, and highly selective enzyme modulators, are being developed to improve efficacy while minimizing toxicity. Additionally, advances in nanoparticle-based delivery systems may enhance the clinical translation of non-coding RNA therapeutics by improving stability, specificity, and intracellular delivery.

Overall, current evidence indicates that epigenetic modulation represents a rapidly evolving field with significant therapeutic potential. Future clinical success will depend on improved biomarker discovery, rational combination strategies, development of selective epigenetic agents, and integration of precision medicine approaches. Continued translational research and well-designed clinical trials are expected to expand the role of epigenetic therapies beyond hematological malignancies into a broader spectrum of solid tumors, ultimately improving patient survival and quality of life.

7. CONCLUSION

Epigenetic modulators have reshaped the therapeutic landscape of cancer by targeting reversible regulatory mechanisms central to oncogenesis. While their most established uses remain in hematologic cancers, expanding evidence supports broader applications-especially in combination strategies and immuno-oncology. Continued innovation in drug design, biomarker discovery, and mechanistic understanding will be essential to hamess the full potential of epigenetics in precision oncology.

8. REFERENCES

1. Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016;8(9):a019505.
2. Jones PA, Issa JPJ, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17(10):630–41.
3. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12–27.
4. Feinberg AP, Koldobskiy MA, Göndör A. Epigenetic modulators, modifiers and mediators in cancer. Nature. 2016;17(5):284–99.
5. Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. Nature. 2013;502(7472):480–8.
6. Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields CE, Niknafs N, Yen RC, et al. Epigenetic therapy ties MYC depletion to reversing immune evasion. Cell. 2017;171(6):1284–1300.
7. Ganesan A, Arimondo PB, Rots MG, Jeronimo C, Berdasco M. The timeline of epigenetic drug discovery. Nat Rev Drug Discov. 2019;18(2):139–58.
8. Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S. Combining epigenetic drugs with immunotherapy. Clin Epigenetics. 2020;12:1–18.
9. Nebbioso A, Tambaro FP, Dell'Aversana C, Altucci L. Cancer epigenetics: Moving forward. PLoS Genet. 2018;14(6):e1007362.
10. Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB. Combining epigenetic and immunotherapy in cancer. Nat Rev Clin Oncol. 2016;13(8):478–90.
11. Xu W, Li J, He C, Wen J, Ma H. Advances in epigenetic therapy for cancer. Signal Transduct Target Ther. 2023;8:112.
12. Dawson MA. The cancer epigenome: Concepts, challenges and therapeutic opportunities. Science. 2022;377:eabq2484.
13. Mohammad HP, Barbash O, Creasy CL. Targeting epigenetic modifications in cancer therapy. Nat Med. 2019;25(3):403–18.
14. Italiano A. EZH2 inhibition in cancer therapy: Current status and future prospects. Cancer Treat Rev. 2021;99:102255.
15. Bennett RL, Licht JD. Targeting epigenetics in cancer. Annu Rev Pharmacol Toxicol. 2018;58:187–207.
16. Lu C, Allis CD. SWI/SNF complex alterations and cancer therapeutics. Cancer Cell. 2017;31(1):9–11.

17. Fazio C, Piazzi G, Vitaglione P. Epigenetic regulation and precision oncology. Cancers (Basel). 2023;15(7):2035.
18. Esteller M. Cancer epigenetics for the 21st century. Nat Rev Genet. 2022;23(6):347–59.
19. Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and therapy resistance in cancer. Science. 2017;357:eaal2380.
20. Issa JPJ, Kantarjian HM. Targeting DNA methylation in cancer therapy: Current applications and future directions. Clin Cancer Res. 2022;28(8):1523–33.